Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
AssigneeGenentech, Inc.
InventorsCanio J. Refino, Stuart Bunting, Daniel Kirchhofer
Life of this patent
Estimating the term…
Abstract
The invention concerns anti-tissue factor (anti-TF) antibodies with enhanced anticoagulant potency, and methods and means for identifying, producing and using such antibodies. The anti-TF antibodies of the present invention are designed to bind to an epitope comprising the C-terminal macromolecular substrate binding region of TF. The invention also concerns methods of treating TF-VIIa related diseases or disorders comprising administering anti-TF antibodies alone or in combination with at least one additional anticoagulant and/or anti-platelet agent.
Claims72
A method of enhancing the antithrombotic efficacy and minimizing an increase in bleeding risk of an anticoagulant comprising:
- administering a dose of anti-TF antibody and a suboptimal dose of at least one additional anticoagulant selected from the group consisting of heparin, low molecular weight heparin, pentasaccharide thrombin inhibotrs and mixtures thereof.
2 A method according to claim 1, wherein the dose of the additional anticoagulant is a dose that does not prolong the activated partial prothrombin time (APTT) more than about 3 fold.
A method of treating a TF-VIIa related disease or disorder, comprising:
- administering to an individual a treatment comprising a dose of an anti-TF antibody and a dose of at least one additional anticoagulant agent selected from the group consisting of heparin, low molecular weight heparin, pentasaccharide thrombin inhibitors and mixtures thereof, wherein the treatment has enhanced antithrombotic efficacy and a minimal increase in bleeding risk compared to administration of the antibody or anticoagulant alone.
A method of treating a TF-VIIa related disease or disorder, comprising:
- administering to an individual a treatment comprising a dose of an anti-TF antibody and a dose of at least one antiplatelet agent, wherein the treatment has enhanced antithrombotic efficacy compared to administration of the antibody or agent alone.
A method of treating a TF-VIIa related disease or disorder, comprising:
- administering to an individual a treatment comprising a dose of an anti-TF antibody and a dose of at least one additional anticoagulant agent or antiplatelet agent, wherein the antibody binds to an epitope comprising at least part of the C-terminal macromolecular substrate-binding region of tissue factor.
A composition comprising:
- a) an anti-TF antibody;
- and
- b) at least one additional anticoagulant or anti-platelet agent, wherein the anticoagulant agent inhibits the formation or growth of a thrombus;
- in admixture with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.